DIOVAN

Compare DIOVAN  to:
Compare
Compare

Generic Name for DIOVAN

Valsartan 40mg+, 80mg, 160mg, 320mg; +scored; tabs.

Legal Classification:

Rx

Pharmacological Class for DIOVAN

Angiotensin II receptor blocker.

Manufacturer of DIOVAN

Novartis Pharmaceuticals Corp

Indications for DIOVAN

Heart failure (NYHA Class II–IV). To reduce cardiovascular mortality in stable post-MI patients with left ventricular failure or dysfunction.

Adult dose for DIOVAN

Heart failure: initially 40mg twice daily, increase to 80mg twice daily, then to 160mg twice daily as tolerated. Post-MI: may start 12hrs post-MI; initially 20mg twice daily, increase within 1 wk to 40mg twice daily; target maintenance: 160mg twice daily as tolerated. Low BP or renal dysfunction: reduce dose.

Children's dosing for DIOVAN

Not recommended.

Contraindications for DIOVAN

Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for DIOVAN

Correct hypovolemia before beginning therapy (may need to reduce diuretic) or monitor closely for hypotension. Hepatic or severe renal impairment. Renal artery stenosis. Severe CHF (if renal function depends on renin-angiotensin-aldosterone system). Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for DIOVAN

Concomitant K+ supplements, K+ sparing diuretics, K+ containing salt substitutes may lead to hyperkalemia and, in heart failure patients, increased serum creatinine. Concomitant ACE inhibitor and β-blocker (see literature regarding heart failure patients).

Adverse Reactions for DIOVAN

Dizziness, hypotension, diarrhea, hyperkalemia, increased BUN, neutropenia, rhabdomyolysis (rare).

How is DIOVAN supplied?

Tabs 40mg—30
Tabs 80mg, 160mg, 320mg—90

Related Disease:

CHF and arrhythmias {CHF and arrhythmias}

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Milrinone lactate injection available in PVC flexible containers

February 16, 2010

Bedford Laboratories announced the addition of milrinone lactate in 5% dextrose injection (0.2mg/mL) in single-dose PVC flexible containers to its existing milrinone injection line.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of CD-NP for treatment of acute heart failure

August 04, 2009

Nile Therapeutics announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.

Multaq available for atrial fibrillation and atrial flutter

July 28, 2009

Multaq (dronedarone tablets), an antiarrhythmic, has been made available by Sanofi-aventis for patients with atrial fibrillation (AF) or atrial flutter (AFL).